Eksenatidi (Finnish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Eksenatidi" in Finnish language version.

refsWebsite

Global rank Finnish rank

68^th place

51^st place

2^nd place

10^th place

5^th place

9^th place

4^th place

12^th place

399^th place

2,670^th place

low place

233^rd place

1researchgate.net

120^th place

243^rd place

731^st place

767^th place

doi.org

dx.doi.org

KV Mann, P Raskin: Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2014, 7. vsk, s. 229–239. PubMed:25018644. doi:10.2147/DMSO.S35331. ISSN 1178-7007. Artikkelin verkkoversio.
JJ Holst: Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia, 2006, 49. vsk, nro 2, s. 253–260. doi:10.1007/s00125-005-0107-1. ISSN 0012-186X. Artikkelin verkkoversio.
KM Janzen et al: GLP-1 agonists in type 1 diabetes mellitus. Annals of Pharmacotherapy, 2016, 50. vsk, nro 8, s. 656–665. doi:10.1177/1060028016651279. ISSN 1060-0280. Artikkelin verkkoversio.

drugs.com

Exenatide Drugs.com. Viitattu 17.1.2020.

europa.eu

ema.europa.eu

Byetta, INN-exenatide (pdf) ema.europa.eu. Viitattu 17.1.2020.
Byetta European Medicines Agency. 17.9.2018. Viitattu 17.1.2020.
Byetta, INN- exenatide (pdf) ema.europa.eu. 2006. Viitattu 18.1.2020.

ec.europa.eu

Bydureon, INN-exenatide (pdf) ec.europa.eu. Viitattu 17.1.2020.

kaypahoito.fi

Juha Saltevo: Eksenatidi kaypahoito.fi. 29.1.2016. Viitattu 17.1.2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

KV Mann, P Raskin: Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2014, 7. vsk, s. 229–239. PubMed:25018644. doi:10.2147/DMSO.S35331. ISSN 1178-7007. Artikkelin verkkoversio.

ncbi.nlm.nih.gov

KV Mann, P Raskin: Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2014, 7. vsk, s. 229–239. PubMed:25018644. doi:10.2147/DMSO.S35331. ISSN 1178-7007. Artikkelin verkkoversio.

researchgate.net

JJ Holst: Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia, 2006, 49. vsk, nro 2, s. 253–260. doi:10.1007/s00125-005-0107-1. ISSN 0012-186X. Artikkelin verkkoversio.

sagepub.com

journals.sagepub.com

KM Janzen et al: GLP-1 agonists in type 1 diabetes mellitus. Annals of Pharmacotherapy, 2016, 50. vsk, nro 8, s. 656–665. doi:10.1177/1060028016651279. ISSN 1060-0280. Artikkelin verkkoversio.

worldcat.org

KV Mann, P Raskin: Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2014, 7. vsk, s. 229–239. PubMed:25018644. doi:10.2147/DMSO.S35331. ISSN 1178-7007. Artikkelin verkkoversio.
JJ Holst: Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia, 2006, 49. vsk, nro 2, s. 253–260. doi:10.1007/s00125-005-0107-1. ISSN 0012-186X. Artikkelin verkkoversio.
KM Janzen et al: GLP-1 agonists in type 1 diabetes mellitus. Annals of Pharmacotherapy, 2016, 50. vsk, nro 8, s. 656–665. doi:10.1177/1060028016651279. ISSN 1060-0280. Artikkelin verkkoversio.